OMERS ADMINISTRATION Corp Makes New $2.13 Million Investment in Medpace Holdings, Inc. $MEDP

Key Points

• OMERS Administration Corp. acquired 4,030 Medpace shares worth approximately $2.13 million in the second quarter. Institutional investors collectively own about 78% of MEDP.
• Medpace recently exceeded quarterly expectations, reporting adjusted EPS of $4.25 and revenue of $707.33 million, up 17.2% year over year. Fiscal 2026 EPS guidance remains between $17.25 and $17.95.
• Despite strong momentum and higher analyst targets, the consensus rating remains “Hold,” with an average price target of $584.18 below recent trading levels. Recent insider selling, including substantial sales by the CEO and a director, may also weigh on sentiment.

OMERS ADMINISTRATION Corp acquired a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 4,030 shares of the company's stock, valued at approximately $2,134,000.

A number of other hedge funds and other institutional investors have also modified their holdings of MEDP. Johnson Financial Group Inc. bought a new stake in Medpace during the second quarter worth about $27,000. Geneos Wealth Management Inc. grew its stake in Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock valued at $29,000 after purchasing an additional 37 shares in the last quarter. Elyxium Wealth LLC acquired a new position in shares of Medpace during the 4th quarter worth approximately $30,000. Allied Private Wealth LLC bought a new stake in shares of Medpace during the 2nd quarter worth approximately $31,000. Finally, Kilter Group LLC acquired a new stake in shares of Medpace in the 2nd quarter valued at approximately $31,000. Institutional investors and hedge funds own 77.98% of the company's stock.

Insider Activity at Medpace

In related news, Director Fred B. Davenport, Jr. sold 7,283 shares of Medpace stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $606.15, for a total transaction of $4,414,590.45. Following the completion of the sale, the director owned 3,798 shares of the company's stock, valued at approximately $2,302,157.70. The trade was a 65.73% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO August J. Troendle sold 27,174 shares of Medpace stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $618.79, for a total transaction of $16,814,999.46. Following the sale, the chief executive officer directly owned 561,195 shares of the company's stock, valued at $347,261,854.05. The trade was a 4.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 125,290 shares of company stock valued at $76,466,988 in the last ninety days. Company insiders own 20.50% of the company's stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on MEDP shares. Royal Bank Of Canada raised their target price on shares of Medpace from $484.00 to $692.00 and gave the company an "outperform" rating in a research note on Friday, July 24th. TD Cowen increased their price target on shares of Medpace from $419.00 to $492.00 and gave the company a "hold" rating in a research note on Friday, July 24th. Leerink Partners set a $620.00 price objective on shares of Medpace in a research report on Thursday, July 23rd. Mizuho boosted their price objective on shares of Medpace from $586.00 to $665.00 and gave the stock an "outperform" rating in a research note on Friday, July 24th. Finally, Barclays set a $600.00 target price on shares of Medpace in a report on Thursday, July 23rd. Three equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. According to MarketBeat.com, Medpace has an average rating of "Hold" and a consensus price target of $584.18.

Key Stories Impacting Medpace

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Medpace remains near a potential technical buy point of $628.92 after its July advance. The stock is trading well above its 50-day and 200-day moving averages, indicating sustained momentum. Medpace Stock Hovers Near Entry, Offers Second Chance After July Spike
• Positive Sentiment: The company’s latest quarterly results exceeded expectations: adjusted earnings were $4.25 per share versus the $3.98 consensus estimate, while revenue rose 17.2% year over year to $707.33 million, surpassing forecasts. Fiscal 2026 EPS guidance remains $17.25 to $17.95.
• Positive Sentiment: Institutional investors and hedge funds own approximately 78% of Medpace, and several investment firms have recently increased their positions. Some analysts have also raised price targets, including RBC’s $692 target and Mizuho’s $665 target.
• Neutral Sentiment: Value-focused investors are comparing Medpace with Concentra Group, but the available report does not establish a clear valuation advantage for MEDP. The stock trades at roughly 36 times earnings, with a PEG ratio above 2.7, suggesting investors are already paying a premium for growth. CON vs. MEDP: Which Stock Should Value Investors Buy Now?
• Neutral Sentiment: Reported short interest was zero shares, producing a zero-day days-to-cover ratio. This provides no meaningful evidence of short-covering demand or downside pressure.
• Negative Sentiment: Several executives have recently sold shares near $620–$625. CEO August Troendle sold 15,978 shares in two transactions worth approximately $9.97 million, while CFO Kevin Brady sold 3,400 shares valued at about $2.13 million. Although both executives retain shares, the concentration of insider selling could weigh on sentiment. Medpace CEO August Troendle Sells 1,983 Shares
• Negative Sentiment: Analyst opinion remains cautious overall: the consensus rating is “Hold,” and the average price target of $584.18 is below recent trading levels. This may make additional upside more difficult without another earnings or guidance catalyst.

Medpace Trading Up 0.8%

Shares of NASDAQ MEDP opened at $619.05 on Thursday. The company has a market capitalization of $17.28 billion, a P/E ratio of 36.29, a P/E/G ratio of 2.74 and a beta of 1.15. Medpace Holdings, Inc. has a 12 month low of $373.00 and a 12 month high of $677.90. The stock has a 50 day moving average of $559.49 and a 200-day moving average of $493.31.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating analysts' consensus estimates of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The business had revenue of $707.33 million for the quarter, compared to analysts' expectations of $689.51 million. During the same quarter in the prior year, the business earned $3.10 EPS. The firm's revenue for the quarter was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Analysts predict that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc NASDAQ: MEDP is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source